Genetic Testing and Parkinson Disease: Assessment of Patient Knowledge, Attitudes, and Interest
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
The most common genetic contributor to late-onset Parkinson disease (PD) is the LRRK2 gene. In order to effectively integrate LRRK2 genetic testing into clinical practice, a strategy tailored to the PD population must be developed. We assessed 168 individuals with PD for baseline knowledge of genetics, perceived risk, and interest and opinions regarding genetic counseling and testing. Most participants felt that they were familiar with general genetics terms but overall knowledge levels were low, with an average score of 55%. The majority of participants thought it was likely they inherited a PD gene (72%), believed genetic testing for PD would be useful (86%), and were interested in genetic testing (59%) and genetic counseling (56%). However, only a few participants had heard of any genetic tests for PD (29%) or LRRK2 (10%). There appears to be a significant level of interest in genetics and genetic testing within the PD population, but a considerable deficit in genetics knowledge and an over-estimation of risk. Genetic education and counseling tools to address these needs were developed to provide patients with the ability to make informed and knowledgeable genetic testing decisions.
- Armstrong, K., Calzone, K., Stopfer, J., Fitzgerald, G., Coyne, J., & Weber, B. (2000). Factors associated with decisions about clinical BRCA1/2 testing. Cancer Epidemiology, Biomarkers & Prevention, 9(11), 1251–1254.
- Biggins, C. A., Boyd, J. L., Harrop, F. M., Madeley, P., Mindham, R. H., Randall, J. I., et al. (1992). A controlled, longitudinal study of dementia in Parkinson’s disease. Journal of Neurology, Neurosurgery and Psychiatry, 55(7), 566–571. CrossRef
- Bowling, B. V., Acra, E. E., Wang, L., Myers, M. F., Dean, G. E., Markle, G. C., et al. (2008). Development and evaluation of a genetics literacy assessment instrument for undergraduates. Genetics, 178(1), 15–22. CrossRef
- Cameron, L. D., Sherman, K. A., Marteau, T. M., & Brown, P. M. (2009). Impact of genetic risk information and type of disease on perceived risk, anticipated affect, and expected consequences of genetic tests. Health Psychology, 28(3), 307–316. CrossRef
- Cappelli, M., Surh, L., Humphreys, L., Verma, S., Logan, D., Hunter, A., et al. (1999). Psychological and social determinants of women’s decisions to undergo genetic counseling and testing for breast cancer. Clinical Genetics, 55(6), 419–430. CrossRef
- Croyle, R. T., & Lerman, C. (1999). Risk communication in genetic testing for cancer susceptibility. Journal of the National Cancer Institute Monographs (25), 59–66.
- Dahodwala, N., Connolly, J., Farmer, J., Stern, M. B., Jennings, D., & Siderowf, A. (2007). Interest in predictive testing for Parkinson’s disease: impact of neuroprotective therapy. Parkinsonism & Related Disorders, 13(8), 495–499. CrossRef
- Daly, M. B., Lerman, C. L., Ross, E., Schwartz, M. D., Sands, C. B., & Masny, A. (1996). Gail model breast cancer risk components are poor predictors of risk perception and screening behavior. Breast Cancer Research and Treatment, 41(1), 59–70. CrossRef
- de Lau, L. M., Schipper, C. M., Hofman, A., Koudstaal, P. J., & Breteler, M. M. (2005). Prognosis of Parkinson disease: risk of dementia and mortality: the Rotterdam Study. Archives of Neurology, 62(8), 1265–1269. CrossRef
- Elbaz, A., Grigoletto, F., Baldereschi, M., Breteler, M. M., Manubens-Bertran, J. M., Lopez-Pousa, S., et al. (1999). Familial aggregation of Parkinson’s disease: a population-based case-control study in Europe. EUROPARKINSON Study Group. Neurology, 52(9), 1876–1882.
- Farrer, M., Stone, J., Mata, I. F., Lincoln, S., Kachergus, J., Hulihan, M., et al. (2005). LRRK2 mutations in Parkinson disease. Neurology, 65(5), 738–740. CrossRef
- Flesch, R. (1948). A new readability yardstick. The Journal of Applied Psychology, 32(3), 221–233. CrossRef
- Goldwurm, S., Zini, M., Mariani, L., Tesei, S., Miceli, R., Sironi, F., et al. (2007). Evaluation of LRRK2 G2019S penetrance: relevance for genetic counseling in Parkinson disease. Neurology, 68(14), 1141–1143. CrossRef
- Healy, D. G., Falchi, M., O’Sullivan, S. S., Bonifati, V., Durr, A., Bressman, S., et al. (2008). Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson’s disease: a case-control study. Lancet Neurology, 7(7), 583–590. CrossRef
- Hoops, S., Nazem, S., Siderowf, A. D., Duda, J. E., Xie, S. X., Stern, M. B., et al. (2009). Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology, 73(21), 1738–1745. CrossRef
- Houfek, J. F., Atwood, J. R., Wolfe, R. M., Agrawal, S., Reiser, G. M., Schaefer, G. B., et al. (2008). Knowledge and beliefs about genetics and smoking among visitors and staff at a health care facility. Public Health Nursing, 25(1), 77–87. CrossRef
- Ishiyama, I., Nagai, A., Muto, K., Tamakoshi, A., Kokado, M., Mimura, K., et al. (2008). Relationship between public attitudes toward genomic studies related to medicine and their level of genomic literacy in Japan. American Journal of Medical Genetics. Part A, 146A(13), 1696–1706. CrossRef
- Kay, D. M., Bird, T. D., Zabetian, C. P., Factor, S. A., Samii, A., Higgins, D. S., et al. (2006). Validity and utility of a LRRK2 G2019S mutation test for the diagnosis of Parkinson’s disease. Genetic Testing, 10(3), 221–227. CrossRef
- Kelly, K., Leventhal, H., Marvin, M., Toppmeyer, D., Baran, J., & Schwalb, M. (2004). Cancer genetics knowledge and beliefs and receipt of results in Ashkenazi Jewish individuals receiving counseling for BRCA1/2 mutations. Cancer Control, 11(4), 236–244.
- Kincaid, J. P., Fishburne R. P. Jr., Rogers, R. L., Chissom, B. S. (1975). Derivation of new readability formulas (Automated Readability Index, Fog Count and Flesch Reading Ease Formula) for Navy enlisted personnel. Research Branch Report. Millington, TN: Naval Technical Training Command, 8–75.
- Klein, C. (2006). Implications of genetics on the diagnosis and care of patients with Parkinson disease. Archives of Neurology, 63(3), 328–334. CrossRef
- Klein, C., & Schlossmacher, M. G. (2006). The genetics of Parkinson disease: Implications for neurological care. Nature Clinical Practice. Neurology, 2(3), 136–146. CrossRef
- Klitzman, R. L. (2010). Misunderstandings concerning genetics among patients confronting genetic disease. Journal of Genetic Counseling, 19(5), 430–446. CrossRef
- Lewis, J. R., Konda, V., & Rubin, D. T. (2009). Genetic testing for inflammatory bowel disease: focus group analysis of patients and family members. Genetic Testing and Molecular Biomarkers, 13(4), 495–503. CrossRef
- Manne, S. L., Chung, D. C., Weinberg, D. S., Vig, H. S., Catts, Z., Cabral, M. K., et al. (2007). Knowledge and attitudes about microsatellite instability testing among high-risk individuals diagnosed with colorectal cancer. Cancer Epidemiology, Biomarkers & Prevention, 16(10), 2110–2117. CrossRef
- Marder, K., Levy, G., Louis, E. D., Mejia-Santana, H., Cote, L., Andrews, H., et al. (2003). Familial aggregation of early- and late-onset Parkinson’s disease. Annals of Neurology, 54(4), 507–513. CrossRef
- Mayeux, R., Denaro, J., Hemenegildo, N., Marder, K., Tang, M. X., Cote, L. J., et al. (1992). A population-based investigation of Parkinson’s disease with and without dementia. Relationship to age and gender. Archives of Neurology, 49(5), 492–497.
- McDaniel, S. H. (2005). The psychotherapy of genetics. Family Process, 44(1), 25–44. CrossRef
- McInerney-Leo, A. (2005). Genetic testing in Parkinson’s disease. Movement Disorders, 20(7), 908–909. CrossRef
- McInerney-Leo, A., Hadley, D. W., Gwinn-Hardy, K., & Hardy, J. (2005). Genetic testing in Parkinson’s disease. Movement Disorders, 20(1), 1–10. CrossRef
- Morren, M., Rijken, M., Baanders, A. N., & Bensing, J. (2007). Perceived genetic knowledge, attitudes towards genetic testing, and the relationship between these among patients with a chronic disease. Patient Education and Counseling, 65(2), 197–204. CrossRef
- Moscarillo, T. J., Holt, H., Perman, M., Goldberg, S., Cortellini, L., Stoler, J. M., et al. (2007). Knowledge of and attitudes about Alzheimer disease genetics: report of a pilot survey and two focus groups. Community Genetics, 10(2), 97–102. CrossRef
- Nasreddine, Z. S., Phillips, N. A., Bedirian, V., Charbonneau, S., Whitehead, V., Collin, I., et al. (2005). The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. Journal of the American Geriatrics Society, 53(4), 695–699. CrossRef
- Ozelius, L. J., Senthil, G., Saunders-Pullman, R., Ohmann, E., Deligtisch, A., Tagliati, M., et al. (2006). LRRK2 G2019S as a cause of Parkinson’s disease in Ashkenazi Jews. The New England Journal of Medicine, 354(4), 424–425. CrossRef
- Paisan-Ruiz, C., Jain, S., Evans, E. W., Gilks, W. P., Simon, J., van der Brug, M., et al. (2004). Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease. Neuron, 44(4), 595–600. CrossRef
- Poewe, W., & Mahlknecht, P. (2009). The clinical progression of Parkinson’s disease. Parkinsonism & Related Disorders, 15(Suppl 4), S28–S32. CrossRef
- Prakash, K. M., Lum, S. Y., Fook-Choong, S., & Tan, E. K. (2006). Knowledge about the genetics of essential tremor in patients and their relatives. European Journal of Neurology, 13(11), 1266–1269. CrossRef
- Rantala, J., Platten, U., Lindgren, G., Nilsson, B., Arver, B., Lindblom, A., et al. (2009). Risk perception after genetic counseling in patients with increased risk of cancer. Hereditary Cancer in Clinical Practice, 7(1), 15. CrossRef
- Rose, A., Peters, N., Shea, J. A., & Armstrong, K. (2005). The association between knowledge and attitudes about genetic testing for cancer risk in the United States. Journal of Health Communication, 10(4), 309–321. CrossRef
- Tan, E. K., & Jankovic, J. (2006). Genetic testing in Parkinson disease: promises and pitfalls. Archives of Neurology, 63(9), 1232–1237. CrossRef
- Tan, E. K., Lee, J., Hunter, C., Shinawi, L., Fook-Chong, S., & Jankovic, J. (2007). Comparing knowledge and attitudes towards genetic testing in Parkinson’s disease in an American and Asian population. Journal of the Neurological Sciences, 252(2), 113–120. CrossRef
- Taylor, C. A., Saint-Hilaire, M. H., Cupples, L. A., Thomas, C. A., Burchard, A. E., Feldman, R. G., et al. (1999). Environmental, medical, and family history risk factors for Parkinson’s disease: a New England-based case control study. American Journal of Medical Genetics, 88(6), 742–749. CrossRef
- Tison, F., Dartigues, J. F., Auriacombe, S., Letenneur, L., Boller, F., & Alperovitch, A. (1995). Dementia in Parkinson’s disease: a population-based study in ambulatory and institutionalized individuals. Neurology, 45(4), 705–708.
- Uitti, R. J., Baba, Y., Wszolek, Z. K., & Putzke, D. J. (2005). Defining the Parkinson’s disease phenotype: initial symptoms and baseline characteristics in a clinical cohort. Parkinsonism & Related Disorders, 11(3), 139–145. CrossRef
- Watner, D., Jurewicz, E. C., & Louis, E. D. (2002). Survey of essential tremor patients on their knowledge about the genetics of the disease. Movement Disorders, 17(2), 378–381. CrossRef
- Zeger, S. L., Liang, K. Y., & Albert, P. S. (1988). Models for longitudinal data: a generalized estimating equation approach. Biometrics, 44(4), 1049–1060. CrossRef
- Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., et al. (2004). Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron, 44(4), 601–607. CrossRef
- Genetic Testing and Parkinson Disease: Assessment of Patient Knowledge, Attitudes, and Interest
Journal of Genetic Counseling
Volume 20, Issue 4 , pp 384-395
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- Parkinson disease
- Genetic testing
- Genetic knowledge
- Perceived risk
- Industry Sectors
- Author Affiliations
- 1. Department of Pathology and Laboratory Medicine, Center for Neurodegenerative Disease Research, University of Pennsylvania, 3600 Spruce St., 3rd flr Maloney, Philadelphia, PA, 19104, USA
- 2. Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, USA
- 3. Department of Neurology, Pennsylvania Hospital, Philadelphia, PA, USA